CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
在澳大利亚血液学环境中建立使用 CAR-T 细胞治疗复发/难治性淋巴瘤的最佳实践
英文原题：Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.
查看英文原题
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自体 CD19 CAR-T（CAR-T）细胞疗法显著改善了许多复发/难治性（R/R）淋巴瘤患者的临床结局。然而，CAR-T 治疗流程专业且复杂，部分原因是输注后会出现特定毒性。目前澳大利亚已有多种 CAR-T 产品可用，但并非所有州都设有治疗中心。本综述旨在为澳大利亚 R/R B 细胞淋巴瘤患者转诊和接受 CAR-T 治疗界定最佳实践，介绍转诊流程、理想患者选择及接受 CAR-T 细胞患者的最佳管理实践。
展开英文摘要原文
Autologous CD19 chimeric antigen receptor T (CAR T)-cell therapies have significantly improved clinical outcomes for many patients with relapsed and refractory (R/R) lymphoma.
However, the process of delivering CAR T-cell therapy is specialised and complex, in part due to specific post-infusion toxicities. Several CAR T-cell products are now available in Australia, although not all states have treatment centres. In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia.
We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells.
论文信息
- 作者
- Dickinson M、O'Leary N、Hamad N、Cochrane T、Ho PJ、Cheah CY、Bishop D、Gregory GP
- 第一作者单位
- Peter MacCallum Cancer Centre, Royal Melbourne Hospital and the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Sydney, New South Wales, Australia.Australia
- 通讯作者单位
- Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.Australia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Internal medicine journal2025 Mar
- 原文标识
- PubMed 40171767 · DOI 10.1111/imj.16544